Arrivent Biopharma target price cut to $27 from $47
AVBP•H.C. Wainwright cut its target price for Arrivent Biopharma to $27 from $47.
Related News
Lexeo Therapeutics to join fireside chat at Chardan Healthcare Conference
LXEO•
Data centers’ flexible power usage could save the grid billions. Can they scale?
NVDA•
EasyJet reportedly sees Apollo takeover on track for completion next year
APO•
Veeva hosts R&D and Quality Summit spotlighting AI innovations in biopharma operations
VEEV•
FrontView REIT cuts target price to $20 from $24
FVR•